We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Read MoreHide Full Article
Haemonetics (HAE - Free Report) shares rallied 17.5% in the last trading session to close at $119.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.4% loss over the past four weeks.
Haemonetics scored a strong price increase on investors’ optimism after CSL announced that it expects to complete the rollout of Haemonetics’ devices and disposables (under the supply agreement) across all CSL’s current U.S. plasma collection centers by the end of calendar 2027. However, the rollout’s scope and timing remain subject to change, with implementation details yet to be finalized by both companies.
This provider blood management systems for health care providers and blood collectors is expected to post quarterly earnings of $1.30 per share in its upcoming report, which represents a year-over-year change of +2.4%. Revenues are expected to be $346.84 million, up 6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Haemonetics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on HAE going forward to see if this recent jump can turn into more strength down the road.
Haemonetics belongs to the Zacks Medical - Products industry. Another stock from the same industry, Cresco Labs Inc. (CRLBF - Free Report) , closed the last trading session 1.3% lower at $0.64. Over the past month, CRLBF has returned -15.2%.
For Cresco Labs Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. This represents a change of +60% from what the company reported a year ago. Cresco Labs Inc. currently has a Zacks Rank of #1 (Strong Buy).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics (HAE - Free Report) shares rallied 17.5% in the last trading session to close at $119.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.4% loss over the past four weeks.
Haemonetics scored a strong price increase on investors’ optimism after CSL announced that it expects to complete the rollout of Haemonetics’ devices and disposables (under the supply agreement) across all CSL’s current U.S. plasma collection centers by the end of calendar 2027. However, the rollout’s scope and timing remain subject to change, with implementation details yet to be finalized by both companies.
This provider blood management systems for health care providers and blood collectors is expected to post quarterly earnings of $1.30 per share in its upcoming report, which represents a year-over-year change of +2.4%. Revenues are expected to be $346.84 million, up 6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Haemonetics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on HAE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Haemonetics belongs to the Zacks Medical - Products industry. Another stock from the same industry, Cresco Labs Inc. (CRLBF - Free Report) , closed the last trading session 1.3% lower at $0.64. Over the past month, CRLBF has returned -15.2%.
For Cresco Labs Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. This represents a change of +60% from what the company reported a year ago. Cresco Labs Inc. currently has a Zacks Rank of #1 (Strong Buy).